Sunesis Pharmaceuticals is a biopharmaceutical company focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The company owns worldwide development and commercialization rights to vosaroxin. For more information, visit the company’s Web site: http://www.sunesis.com
Let us hear your thoughts below:
